What You Should Know:
– Vevo Therapeutics, an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients.
– Vevo is the first platform to make in vivo data generation scalable with single-cell precision + will create the world’s largest atlas of how drugs interact with patient cells. In a single in vivo experiment, Mosaic can measure how a drug impacts cells from hundreds of patients, generating millions of datapoints on drug-induced changes in gene expression.
– With the seed funding, Vevo will perform thousands of Mosaic experiments to create what is deemed impossible today: an in vivo atlas of how chemistry perturbs biology. Vevo’s AI models will be trained on this atlas to uncover novel targets and drugs undetectable by other technologies.
– Vevo will combine its atlas with AI models to capture in vivo context of disease and better represent patient diversity in drug response over current in vitro assays. For example, in a single in vivo experiment, the company can measure how a drug impacts cells from hundreds of patients, generating millions of data points on drug-induced changes in gene expression.